Gujarat Terce Laboratories Limited has announced a board meeting scheduled for February 4, 2026, to review and approve the company's unaudited standalone financial results for the third quarter and nine months ending December 31, 2025. The pharmaceutical company communicated this development to BSE Limited on December 28, 2025, in accordance with regulatory requirements.

Board Meeting Details

The meeting will be held on Wednesday, February 4, 2026, where the Board of Directors will consider and approve the unaudited standalone financial results for Q3FY26. The company has issued this notification pursuant to Regulation 29 read with Regulation 50 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Trading Window Closure

In compliance with the company's Code of Conduct for Prevention of Insider Trading in Securities, Gujarat Terce Laboratories has announced the closure of the trading window. The restriction will be effective from January 1, 2026, to February 6, 2026, with both days being inclusive in the closure period.

Regulatory Compliance

The announcement demonstrates the company's adherence to regulatory frameworks governing listed entities. The notification has been made available on the company's official website at https://www.gujaratterce.in/ to ensure transparency and accessibility for all stakeholders. Company Secretary Ashka Solanki has digitally signed the communication on December 28, 2025, at 11:32:54 +05'30', confirming its authenticity and official nature.

This scheduled board meeting represents a routine corporate governance activity as the company prepares to disclose its financial performance for the third quarter of the fiscal year 2026.

Gujarat Terce Laboratories Limited has completed the conversion of 3,71,000 fully convertible warrants into equity shares and subsequently filed a substantial acquisition disclosure under SEBI regulations. The pharmaceutical company announced the warrant conversion in a regulatory filing to BSE Limited, followed by a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Warrant Conversion Details

The conversion involved Mr. Aalap Natubhai Prajapati, the Promoter Managing Director of the company, who exercised his entire warrant holding. The key parameters of the conversion are presented below:

The company received the balance consideration of ₹1,04,90,025, in addition to the upfront payment of ₹34,96,675 received at the time of warrant allotment. These warrants were originally allotted on preferential basis.

Impact on Share Capital Structure

The warrant conversion has resulted in changes to the company's issued, subscribed, and paid-up capital structure:

The newly allotted equity shares rank pari-passu with existing equity shares in all respects, including dividend payment and voting rights.

SEBI Disclosure Under Regulation 29

Following the warrant conversion, Mr. Aalap Natubhai Prajapati filed a substantial acquisition disclosure with BSE on December 17, 2025. The disclosure details his shareholding pattern changes:

SEBI SAST Regulation 10(2B) Declaration

In compliance with regulatory requirements, Mr. Aalap Natubhai Prajapati also filed a declaration under Regulation 10(2B) of SEBI (SAST) Regulations, 2011. The declaration confirms that all conditions specified under the regulation for exemptions have been duly complied with:

The acquisition involved 3,71,000 equity shares of face value ₹10.00 each acquired through conversion of warrants allotted on preferential basis. The warrants were originally allotted and subsequently converted into equity shares on December 16, 2025.

Regulatory Compliance

The allotment was approved by the Board of Directors in compliance with SEBI regulations. The company has applied for listing and trading approval of the newly allotted shares with BSE Limited. The shares are pending credit and exchange approval as per the latest filing.

The conversion represents a successful completion of the preferential allotment process, providing the company with additional capital of ₹1.40 crores while demonstrating continued promoter commitment to the pharmaceutical business.